NASDAQ: SVA

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs
CompanyDrug

Mabwell to Present Phase II Data for Nectin‑4 ADC 9MW2821 at ESMO 2026 – 30.0% ORR in Post‑TOP1i‑ADC Triple‑Negative Breast Cancer, Headlining Four Phase III Programs

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062; HKG: 2493) announced that it will present, as an oral report, Phase II clinical data for 9MW2821 – its innovative Nectin‑4‑targeted antibody‑drug conjugate…

EMA's CHMP Backs Flexible Dosing for Regeneron's Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer

CompanyDeals

Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer

Company

Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom

CompanyDeals

Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production

CompanyDrug

Sinovac’s Hepatitis A Vaccine Healive Approved in Egypt

CompanyDeals

VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant

Company

Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline

CompanyDrug

WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above

Show More